We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Arbutus Biopharma (ABUS - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Arbutus Biopharma is one of 1021 individual stocks in the Medical sector. Collectively, these companies sit at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Arbutus Biopharma is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ABUS' full-year earnings has moved 2.6% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, ABUS has returned 44.8% so far this year. At the same time, Medical stocks have gained an average of 4.5%. This shows that Arbutus Biopharma is outperforming its peers so far this year.
Annexon, Inc. (ANNX - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 19.2%.
For Annexon, Inc. the consensus EPS estimate for the current year has increased 28.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Arbutus Biopharma belongs to the Medical - Biomedical and Genetics industry, a group that includes 499 individual stocks and currently sits at #93 in the Zacks Industry Rank. On average, this group has lost an average of 2.9% so far this year, meaning that ABUS is performing better in terms of year-to-date returns. Annexon, Inc. is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on Arbutus Biopharma and Annexon, Inc. as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Arbutus Biopharma (ABUS - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Arbutus Biopharma is one of 1021 individual stocks in the Medical sector. Collectively, these companies sit at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Arbutus Biopharma is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ABUS' full-year earnings has moved 2.6% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, ABUS has returned 44.8% so far this year. At the same time, Medical stocks have gained an average of 4.5%. This shows that Arbutus Biopharma is outperforming its peers so far this year.
Annexon, Inc. (ANNX - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 19.2%.
For Annexon, Inc. the consensus EPS estimate for the current year has increased 28.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Arbutus Biopharma belongs to the Medical - Biomedical and Genetics industry, a group that includes 499 individual stocks and currently sits at #93 in the Zacks Industry Rank. On average, this group has lost an average of 2.9% so far this year, meaning that ABUS is performing better in terms of year-to-date returns. Annexon, Inc. is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on Arbutus Biopharma and Annexon, Inc. as they attempt to continue their solid performance.